Introduction
New developments and innovations in technologies for toxicity testing and biomonitoring present an invaluable opportunity to improve current risk assessment methodologies and their contribution to regulatory decision-making processes. Recent reports from the National Academy of Sciences (NAS, 2006 (NAS, , 2007a describe the potential for a true paradigm shift in toxicity testing that takes advantage of recent revolutionary changes in technologies for biology and biotechnology. These new technologies provide sensitive approaches for detecting genetic and metabolic changes in cells and tissues as well as for detecting the presence of low levels of compounds in biological samples. However, important questions have emerged concerning the extensive data sets that these new technologies can generate. How can data primarily from in vitro assay systems be appropriately interpreted in the absence of interactions with the complex biological systems from which the samples originated? How do changes in these model test systems relate to apical end points that have traditionally been used in toxicology? How can relevant exposure and dose information be collected so that clear links can be drawn between the biological observations and the environmental exposure conditions? How can this information be applied to improve our understanding of risk and the decisions related to the regulatory process?
A workshop, titled Twenty-First Century Approaches to Toxicity Testing, Biomonitoring and Risk Assessment, was organized to stimulate interactions and discussions among a variety of stakeholders regarding implementation of the new technologies towards improved assessment of human health risks, with an emphasis on research, development, and advancement of the new methods. A clear benefit of such improvements in risk assessment would be to better inform the regulatory decision-making process.
Workshop organization
This workshop, among the first international meetings focusing on this topic, was held on 16-17 June 2008 in Amsterdam in the Netherlands. It was organized and sponsored by the ICCA-LRI, which comprises the Long-Range Research Initiatives (LRIs) of the American Chemistry Council, (the European Chemical Industry Council), and the Japanese Chemical Industry Council. The workshop was part of the ICCA-LRI's global research strategy to strengthen the scientific foundation for public policy and decision making through support of quality research regarding the effects of chemicals on human health and the environment. More than 150 participants, including scientists, public health/public policy professionals, industry representatives and communicators from academia, governmental/nongovernmental organizations from the United States, Canada, Europe, and Japan attended the workshop.
This report summarizes the discussions and recommendations that emerged from the workshop that helped the ICCA-LRI plan its next generation of research programs. It does not represent a consensus document among the workshop attendees. A complete report can be found on 2008 ICCA-LRI Workshop Report.
Context for the workshop
The primary motivation for this workshop was the rapidly emerging shift in thinking about the use of new technologies to evaluate human health and environmental risks in the twenty-first century. Science, technology, and innovative thinking are all essential tools for addressing the variety of global concerns regarding environmental health risks. Enabling this paradigm shift will require significant capacity building as well as dialog and collaborations between scientists and policy experts from all sectors, including industry, academia, and governmental and non-governmental organizations.
The new technologies present an exciting opportunity to extend beyond traditional risk assessment approaches and to better understand the effects of chemicals on humans and the environment. They are particularly relevant for clarifying our understanding of potential adverse effects from exposures to the low levels of chemicals present in our environment. The new technologies include toxicogenomics that combines the tools of traditional toxicology with those of genomics as well as bioinformatics and high-throughput screening (HTS) assays that can be used to evaluate changes in gene, protein, and metabolite profiles in cell and tissue samples (Waters and Fostel, 2004; Hayes and Bradfield, 2005; . Many of these new technologies were originally developed by the pharmaceutical industry for rapid toxicity screening of potential drug candidates. Numerous governmental and academic organizations were also involved in the development and refinement of these technologies. This knowledge base provides an unprecedented leverage to develop related approaches for rapidly assessing the potential toxicities of chemical compounds in the environment.
At present, determination of human health risks from exposures to chemicals is based primarily on results from animal model toxicity studies that involve exposures at doses that can far exceed every day human exposure levels. These results are then adjusted with a variety of factors to extrapolate from high-dose to low-dose effects, to account for species differences between animals and humans, and to determine levels at which no effects or minimal effects are likely to occur. Several drawbacks of these traditional toxicity studies are that they usually take years to complete, they are very costly, and they can use a large number of animals. An additional drawback is that the adjustment factors used may not fully account for metabolic differences between humans and animals that can alter toxicological outcomes.
A majority of scientists in the fields of risk assessment and toxicology acknowledge that the long-term, high-dose exposure regimens used for animal models yield results that may not be biologically relevant to the potential adverse effects and risks from real-world exposures to chemicals for humans (Conolly et al., 1999) . The new technologies, such as toxicogenomics, can in weeks to months provide extensive information about modifications in cells and tissues following exposures to chemicals at a variety of concentrations. However, the key current question is how best to interpret the volume of data documenting these in vitro modifications in a way that is relevant for predicting potential adverse changes/outcomes in whole organisms and that is relevant to the changes observed in the longer term animal exposure models. One example is a current lack of understanding regarding changes in gene-expression profiles and potential downstream consequences for cells, tissues, and organisms. Meaningful interpretation of the data from the new technologies will be essential for using these new technologies to improve the regulatory decision-making process.
The 2007 report from the NAS, titled Toxicity Testing in the 21st Century: A Vision and a Strategy, which describes the new technologies for evaluating environmental health risks, was a major focus for the workshop (National Academy of Sciences, 2007a) . The basis for the new paradigm is use of the new technologies to detect activation of toxicity pathways, which the report generally defines as cellular response pathways that, when sufficiently perturbed, can result in adverse pathological outcomes. Changes in gene, protein, and metabolite profiles following exposures to chemical compounds or environmental stressors can be identified with the new technologies and used to identify cellular and tissue changes that may portend activation of toxicity pathways. One intended goal for these new analytical approaches is to begin to use the data in place of traditional apical end points, such as gross physiological and pathological changes including tissue damage and tumor formation, from the longer term and more costly studiesy . However, as noted in the NAS report a critical prerequisite for meaningful use of the data from the new technologies will be the ability to distinguish between the changes representing perturbations in cells or tissues that may resolve themselves through normal homeostatic mechanisms and those changes indicating true activation of toxicity pathways that may lead to true pathology. A further need is the need to determine if all perturbations are adverse, whether or not they resolve when the causative agent is removed.
The benefits envisioned through use of the new technologies to generate toxicity test data and improve the risk assessment and decision-making processes are numerous. The computational or in silico methods that are the core of the approach have the potential to increase the number of chemicals and end points that can be evaluated while decreasing both the time and costs required to complete the assays and the number of animals used for testing. The results can be a source of detailed mechanistic and dose information relevant to human health risk assessment.
The report acknowledges that a substantial commitment of resources will be required to implement the vision that has been outlined. In addition, successful implementation of this new paradigm in toxicity testing will require support from the scientific community, regulators, law-makers, industry, and the public. Last, but not the least, effective communication among all of these parties regarding the development and ultimate value of these new methodologies will be a key to its success.
European perspectives on the use and potential value of the new technologies for addressing current issues regarding the evaluation of chemical toxicity in the European Union (EU) were an integral part of the workshop discussions. Two direct applications include compliance with the testing requirements under the new legislation for chemicals, called the Registration, Evaluation, Authorization and Restriction of Chemicals Regulation, and the recent EU-wide ban on animal use for cosmetics development. It is anticipated that the in vitro methods that constitute the core of the new technologies can accelerate completion of required testing while reducing costs and animal usage. However, the challenges to the new technologies will be to meet the requirements for international validation.
A number of emerging toxicogenomic testing projects and programs were discussed at the Workshop. Several in vitro test projects that are in use or under development in Europe, such as Predictomics, ReProTect and TOXDROP, employ novel techniques for determining chemical toxicity. Another European collaborative project, carcinoGENOMICS, is using several 'omic platforms from genomics to metabonomics with novel bioinformatics and test systems, such as stem cells, to assess the potential of these methods to screen for genotoxic and carcinogenic properties of chemical compounds in vitro. This alternative to rodent bioassays can test genotoxic and non-genotoxic carcinogens and ultimately would be used to develop a battery of organ-specific genomics-based in vitro assays that will be submitted to the European Centre for the Validation of Alternative Methods. In the area of biomonitoring, a food quality and safety program is aimed toward identifying biomarkers of exposure for chemicals of relevance to human health and disease. In addition, NewGeneris is an in vivo regime that will employ biomarkers of dietary exposure to genotoxic and immunotoxic chemicals, as well as biomarkers of early effects using mother-child birth cohorts and biobanks. All of these test regimes support the EU's progression towards the use and application of the new technologies of transcriptomics, proteomics, metabonomics, and bioinformatics.
In the United States, two major research efforts are focusing on in vitro approaches as alternatives to traditional animal toxicity testing. In 2007, US EPA's National Center for Computational Toxicity (NCCT) launched ToxCast to develop a cost-effective in vitro approach for prioritizing toxicity testing for the large number of chemicals in a short period of time (Dix et al., 2007) . In response to the release of the 2007 NRC report, two NIH institutes and EPA NCCT formed a collaboration, called Tox21 that has been designed to (1) identify mechanisms of chemically induced biological activity, (2) prioritize chemicals for more extensive toxicological evaluation, and (3) develop more predictive models of in vivo biological response (Austin et al., 2008; Collins et al., 2008) . Tox21 is an innovative approach to build complementary capacity across different governmental agencies, and to broaden stakeholder collaborations for addressing emerging scientific needs. Tox21 is expected to deliver biological activity profiles that are predictive of in vivo toxicities for thousands of substances of importance to regulatory authorities in the United States, as well as in many other countries.
Biomonitoring and its applications for public health issues within an evolving risk framework were another major focus of the workshop. Biomonitoring data reflect ongoing or previous exposures to chemicals based on measurements of the chemicals themselves or their metabolites in fluid and tissue samples, such as human blood and urine (National Academy of Sciences, 2006) . Some of the current challenges for biomonitoring include proper identification of exposure sources, understanding the impacts of sampling methods on quantification of exposure, determining the potential effects of mixed exposures, and a lack of relevant toxicity values to interpret the data, particularly among susceptible individuals, such as children and the elderly.
Through its biomonitoring research program, the ICCA-LRI has explored the linkages between biomonitoring data and environmental exposures. The relationships among biomonitoring, real-world exposures, and recent innovations in technology for toxicity testing could be synergized through a global coordination effort by LRI. Such a coordinated effort could provide great value to the chemical industry by improving the understanding of the potential effects of chemicals at environmentally relevant exposure levels.
Biomonitoring assay methods now have exquisite sensitivity to detect chemicals and metabolites in samples at the parts per billion and the parts per trillion levels. Key question that emerge related to these enhanced detection limits are whether and how the measured levels potentially link to predictions for potential adverse health outcomes and what is the relevance of the detection limits for characterizing true population exposures.
A current trend in biomonitoring research is the use of existing risk-based approaches as a context for the measurement results, such as converting a measured biomarker level to a dose level in humans or animals using physiologically based pharmacokinetic (PBPK) modeling. These PBPK models use computer-based approaches to combine information about the physiology and anatomy of an animal or the human body to understand the biochemistry and metabolism of the chemical or chemicals of interest following an exposure. Future directions for improved biomarkers include their use in epidemiological studies to define biomonitoringresponse relationships and to help set research priorities. Another future focus for biomonitoring studies is to extend beyond measurements of body burden to applications that will facilitate the understanding of health end points and exposure sources.
Parallel sessions
Three parallel sessions were convened following the workshop's opening plenary sessions to provide an opportunity for more detailed interactions and discussions among speakers and participants regarding three major themes for the workshop: biomonitoring, advanced technologies, and risk assessment.
Human biomonitoring
This session explored the links between biomarkers of exposures and environmental exposures and how advancements in technologies, such as biological or environmental monitoring and modeling, can facilitate these connections and subsequent interpretation of human biomonitoring data. The aim was to showcase new developments in quantitative and qualitative interpretation and application of biomonitoring data and to present opportunities that would advance their application to public health issues. Three relevant topics included: (1) how biomonitoring data are currently being used in large population studies; (2) reports of new biomonitoring data as well as information on new trends and planning efforts; and (3) current thinking on modeling and statistical approaches to improve dose and exposure estimates.
Several large ongoing biomonitoring studies by public health organizations demonstrate both the benefits and complexities inherent in biomonitoring studies. A number of the large ongoing studies were discussed as examples. The German Health Interview and Examination Survey for Children and Adolescents (KiGGS) study has evaluated more than 17,000 German children up to the age of 17 years (Robert Koch Institute (RKI), 2005). These collected data include objective measures of physical and mental health as well as parental or self-reported information about subjective health status, health behavior, health care utilization, social and migrant status, living conditions, and environmental determinants of health. The German Environmental Survey on Children (GerES) has examined exposures and exposure pathways to environmental pollutants, including metals, pesticides, and selected chemical compounds, in a subset of children 3 to 14 years of age who are part of the KiGGS study (Umweltbundesamt (UBA), 2008). Data from both of these studies now allow evaluation of relationships between environmental conditions and the health of children in Germany.
Two major biomonitoring initiatives by the Centers for Disease Control and Prevention, The National Reports on Human Exposure to Environmental Chemicals and the National Health and Nutrition Examination Survey, were reviewed as examples of large biomonitoring studies in the United States (CDC, 2007) .
Discussions about these biomonitoring studies highlighted the challenges they present, including the specificity of any given biomarker, its persistence in the body, the limits of analytical sensitivity for detecting a biomarker, intra-person and inter-person variabilities in the results and ultimately how to link the results to actual exposures. Differences between reference values, which are health-based and accepted widely, and human biomonitoring (HBM) values, which are not health-based, were reviewed. The discussants noted that reference values are statistically derived as average values for a sample population, whereas HBM values are used to identify concentrations above and below which adverse health effects may occur.
Reverse dosimetry is a method for estimating exposure and risk from human biomonitoring data (Clewell et al., 2008) . The method involves probabilistic dose reconstruction at the population level and human pharmacokinetic modeling to describe the relationship between the biomarker and external dose. The method may also require information about the nature of the exposure, such as source, frequency, and duration. It can be a useful approach in the absence of a direct link between a biomarker and health outcomes, but a confounding issue is the uncertainty and variability in human exposures and pharmacokinetics.
Another recent development is biomonitoring equivalents (BE). The BE approach can use human biomonitoring data for a variety of compounds and then draw upon existing risk assessment information for those compounds to provide a tool for the interpretation of biomonitoring data in a health risk assessment context. BE values are based on transformation of human tolerable daily intake values, which have been derived from existing risk assessments and include animal toxicity data, using pharmacokinetic modeling approaches (Hays et al., 2007 (Hays et al., , 2008 . BEs developed for specific chemicals that may be present in blood, urine, or other human samples are designed to be consistent with existing exposure guidance values, such as reference doses and reference concentrations. They can serve as a communication tool for placing population-based biomonitoring results in a public health-risk context and for informing chemical prioritization decisions regarding the need for further risk assessment or for risk management decisions.
The discussions during the session identified a number of challenges for the use and interpretation of biomonitoring data. To use biomonitoring data for effective intervention or risk management strategies, a link has to be established between external sources and the pathways for exposure. This presents a particular challenge for cumulative exposures that include multiple chemicals and the potential for interactions among these chemicals. More specific biomarkers of exposure and improved designs for both exposure and epidemiological studies that will elucidate these linkages are required. Biomonitoring data should be considered among the full suite of information gathered for exposure analysis studies, and to that end, collection of relevant peripheral data through questionnaires and personal/environmental monitoring is also essential. Biological specimens stored under proper conditions could be banked for future analyses that would use new methods as they are developed. The absence of quality standards for most biomarkers and uncertainty in laboratory analysis also present limitations for biomonitoring methods. However, further development and refinement of approaches that more clearly link biomonitoring results back to exposure, such as reverse dosimetry and BEs, will be valuable elements for improving risk assessment and fostering more effective risk management decisions for the general public.
Advanced technologies
Discussions about the advanced technologies presented an opportunity to review recent developments that utilize toxicogenomics and HTS assays as well as a systems biology approach. Two objectives that have been identified for these new technologies are to provide toxicity (hazard) screening information for a large number of chemicals and to provide mode of action information to guide understanding of risk assessment (National Academy of Sciences, 2007a) . The session focused on understanding the similarities and differences among ongoing studies that are utilizing the new technologies, identifying areas for cooperation, maximizing value from the programs, and identifying a role for ICCA-LRI to address potential underemphasized areas.
Discussions included the types of information that these various technological approaches can produce and how they might be useful for risk assessment. As noted previously, a key element of the paradigm shift for the use of these new technologies is to move the focus from thinking about changes in single genes towards impacts on multiple genes that constitute toxicity pathways. Related to the recent NAS (2007b) report on applications of toxicogenomic technologies to predictive toxicology and risk assessment, a potential benefit of these new technologies would be evaluation of the shape of dose-response curves for chemicals at levels relevant to real-world human exposures. A key question is whether genomic technologies can be successfully used to identify and characterize key event changes in cells and tissues in this lowdose region.
The Tox21 program uses quantitative HTS to identify biological activities for large chemical libraries. Traditional HTS approaches used by the pharmaceutical industry for drug discovery have the capacity to evaluate more than 100,000 chemicals per day. However, only one dose per compound is generally evaluated and high rates of false positives and false negatives can occur. Tox21 uses 15 different concentrations for each compound and produces robust biological activity profiles for human and animal cells; they include evaluation of viability, enzymatic pathways, and nuclear receptor assays that have low rates of false positives and false negatives.
In Europe, the EU-Framework Programme 6 PredTox Project used an integrated toxicogenomics approach for mechanistic biomarker identification. The project focus was an in vivo rat study that evaluated toxicities in the liver and kidneys caused by selected drug candidates using samples of liver, kidney, blood, and urine. The study protocol incorporated conventional end points, such as clinical chemistry and histopathology, with transcriptomics, proteomics and metabonomics. The objective of the study was to explore the sensitivity of ''omic methods'' as predictive systems with short and low-dose exposures. These data would be applied to increase the understanding of toxicity mechanisms and to evaluate use of the new technologies to identify potential biomarkers in tissue samples and fluids.
A current challenge for the use of genomics in toxicology lies in our ability to use these tools together with other relevant molecular approaches to determine whether changes in gene expression can be used as indicators of adverse biological responses to a toxic exposure. It is anticipated that specific mechanisms of toxicity will elicit specific patterns of gene expression; whether these patterns are conserved across species is an additional question that remains to be answered. For predictive toxicology, the question remains whether use of ''omics'' data can improve understanding of mechanisms of toxicity. However, which toxicity parameters should be evaluated in-depth and whether genomics can improve the performance of in vitro models are areas for continued research. One concern is that while the costs of generating the data will likely decrease, the costs for interpreting the data are likely to increase due to their quantity and complexity. As the function of more genes, and consequently more networks, is understood, reevaluation of previously generated ''omics'' data will also be needed. Although these directions suggest future scientific and financial challenges, they should not mitigate generation of data, but only emphasize the importance of relevant data interpretation.
It also remains to be determined whether the new technologies can inform current operational assumptions in toxicity testing and risk assessment. Examples of potential tests of these assumptions include examination of the current routine application of a linear, no-threshold approach for risk assessments of genotoxic substances and determination of whether traditional maximum-tolerated dose approaches that use pathology and/or organ and body weight effects can be refined to align with effects identified with toxicogenomics. The new approaches are also drivers for devising new toxicological terms, such as no observed transcriptional effect level; however, the application of such concepts to future risk assessment will require further consideration. In addition, the workshop participants noted an opportunity to apply toxicogenomic approaches to further explore and refine the use of Toxic Equivalency Quantity and Toxic Equivalency Factor defaults that are currently used to characterize risks from chemical mixtures. Additional opportunities remain to reexamine current use of multiple uncertainty factors in risk assessments and to replace the uncertainty defaults with databased information.
Risk assessment
The new technologies present challenges to risk assessment practitioners to determine how to translate the large volumes of data into meaningful information that can be considered in public health decision making. A companion challenge is how to effectively communicate these data to the medical community, the public, and the media. To remain relevant, risk assessment approaches will need to be modified to be more dynamic and responsive to this oncoming deluge of information. Workshop participants discussed the need for a significant paradigm shift in risk assessment approaches.
The NAS (2007a) report highlighted population-level exposure data as a critical element to inform toxicity testing, to describe risk and to place risk into a real-world context. Implementation of this aspect of the vision will require a systems-based incorporation of exposure and its interaction with effect (Cohen Hubal et al., 2008; Edwards and Preston, 2008; Sheldon and Cohen Hubal, 2009) . New predictive tools and databases will need to be developed to characterize exposure and dose and then to link this information to toxicity data.
Looking at a path forward, a possible first step would be to use a problem formulation approach and the available data sources as anchors for that process. Such sources could include the large databases of the physical and chemical properties of chemicals as well as existing use and exposure information. The large volumes of available data that can serve as a bridge to future understanding include structureactivity relationships and the extensive databases on human health, such as epidemiology data for a number of chemicals, animal toxicity pathways, and mode of action information.
Questions do remain whether elements of the existing risk assessment framework can inform or be used to develop a new framework and what first steps would be needed to create such a framework. One key to success will be to invest the time needed to better understand the potential complexities of the toxicity pathways discussed in the NAS (2007a) report; this step will be critical to establish a valid bridge from existing animal data to toxicity pathways in humans.
Perspectives and path forward
Participation at the workshop by academics, regulators, and industry and government representatives was invaluable for obtaining input and feedback from a variety of perspectives. This blend of expertise enhanced the process of identifying research gaps and of defining research directions that will lead to better understanding of the potential impact of chemicals on human health and the environment. The workshop underscored the chemical industry's commitment to research for developing 21st century approaches to toxicity testing, exposure science, and risk assessment. One clear outcome of the workshop was support from across the range of attendees for future research efforts to advance exposure science to improve the ability to characterize exposures in an environmentally relevant context. To complement the advances in toxicity testing and risk assessment, corresponding advances in exposure science will be needed to characterize relevant exposure with an efficiency and scale commensurate with the toxicity testing initiatives.
A number of observations emerged from the workshop that helped shape the path forward for ICCA-LRI research planning. They are summarized here:
New science and technology can be instrumental for creating a paradigm shift in risk assessment. To engage in a rational debate about a new paradigm, a commitment must be made to fill the information gap. Public perception of risk involves many personal beliefs, judgments, attitudes, and feelings. Increased access to data may improve public perceptions of risk, but it also carries the potential for misuse and misinterpretation of the data and for decreased societal receptivity to innovation.
Timely and relevant communication strategies will be essential for effectively distributing information throughout the network of stakeholders. The move from identifying hazards to identifying risks will require targeted studies to understand and map toxicity pathways. Essential elements include comprehensive in vitro studies, preferably with human cells, computational maps of the toxicity pathways, and underpinning the analysis of pathways with support of basic science to elucidate and analyze perturbations in those pathways. The balance of financial commitment to the new technologies will shift from data generation to data interpretation as more high-throughput technologies are employed. Understanding the potential effects of exposures to chemicals in early life and the influence of genetic susceptibility, including polymorphisms, are critical. The emerging technology enables characterization of genetic polymorphisms; however, proper interpretation and understanding of the data will require much research, such as full evaluation over the complete range of doseresponse. Fundamental to improving risk assessment with the new technologies are the needs to relate in vitro doses to in vivo exposures and to characterize dose-response relationships. Gene expression may identify a hazard, but a true assessment of risk requires relevant dose-response data and mechanistic understanding of the relevant toxicity pathways, particularly at low doses. A key question is how the new toxicity information will be translated to assess the potential for real-world human health risks. A paradigm shift in risk assessment requires a priori and commensurate consideration of the totality of the paradigm and an understanding of the real-world context of population exposures. Population-based data and human exposure information will be critical for guiding development and use of toxicity information. Requisite components of population information include: information on host susceptibility and background exposures to interpret and extrapolate in vitro test results; human exposure data to select doses for toxicity testing so that hazard information on environmentally relevant effects can be developed; and biomonitoring and biomarker data to relate real-world human exposures with concentrations that perturb toxicity pathways to identify potential exposures. To realize the vision of NRC (2007a) report, a strategic and fully integrated systems approach is required. This approach can be actualized through a coordinated and sustained investment not only to develop technologies, but also to interpret the emerging data in the context of population health. Scientific and regulatory acceptance of the new toxicity testing approaches should be fostered through peerreviewed research, established test protocols, and validated models. Importantly, this acceptance should emerge from a robust, multi-stakeholder dialog, as evidenced at this workshop, with its focus on design, interpretation, and application of these complex, but informative technologies to risk assessment.
A specific aim of the workshop was to stimulate a discussion on the scientific basis for policy-making, to understand how these new technologies can have a role in risk assessment and to build a consensus to move the risk assessment process forward. The recent emergence of these new technologies offers an unprecedented opportunity to advocate effectively and proactively for science-based decision making, to formulate better decisions about potential effects from exposures to chemicals, and to speak to the safety of chemical from a stronger scientific basis. The perspectives and observations from the workshop that are summarized above can serve as a starting point for ICCA-LRI research to synergize the use of these new technologies toward those ends.
